Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the drug ADX-038 in participants aged 60 years and older who have geographic atrophy GA secondary to age-related macular degeneration AMD. This Phase 2, randomized, masked, placebo-controlled study aims to compare the effects of ADX-038 with a placebo on preserving the ellipsoid zone EZ layer in the eye over 12 months. The trial will also assess the safety, pharmacokinetics, and pharmacodynamics of ADX-038. Participants will receive either subcutaneous injections of ADX-038, a siRNA duplex oligonucleotide, or a saline placebo. The study uses a parallel design where participants are randomly assigned to one of these two groups. The treatment is administered over a 12-month period, during which the impact on eye structure and function will be closely monitored. Throughout the study, participants will attend clinic visits for assessments, including high-quality fundus imaging and other study-related procedures. They must complete meningococcal and pneumococcal vaccinations as required by the protocol. Researchers will monitor the preservation of the EZ layer as the primary outcome to evaluate treatment effect, alongside safety and drug behavior in the body. The total study duration extends until August 2030, with primary outcome results expected by February 2030.